Is SRZN or BHST more profitable?

BioHarvest Sciences has a net margin of -32.54% compared to Surrozen's net margin of -4,810.50%. BioHarvest Sciences' return on equity of -76.03% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% BioHarvest Sciences -32.54% -76.03% -25.30%

Do analysts rate NLTX or BHST?

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 181.61%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

BioHarvest Sciences (BHST) Competitors

$3.55 +0.35 (+10.97%)

As of 10:00 AM Eastern

Compare

BHST vs. SRZN, NLTX, MGNX, TRDA, and FULC

Should you buy BioHarvest Sciences stock or one of its competitors? MarketBeat compares BioHarvest Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioHarvest Sciences include Surrozen (SRZN), Neoleukin Therapeutics (NLTX), MacroGenics (MGNX), Entrada Therapeutics (TRDA), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry.

How does BioHarvest Sciences compare to Surrozen?

Surrozen (NASDAQ:SRZN) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Surrozen had 3 more articles in the media than BioHarvest Sciences. MarketBeat recorded 4 mentions for Surrozen and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat Surrozen's score of 0.93 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Surrozen	Positive
BioHarvest Sciences	Very Positive

BioHarvest Sciences has a net margin of -32.54% compared to Surrozen's net margin of -4,810.50%. BioHarvest Sciences' return on equity of -76.03% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has higher revenue and earnings than Surrozen. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	37.14	-$242.03M	-$37.59	N/A
BioHarvest Sciences	$35.16M	1.98	-$11.14M	-$0.59	N/A

Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Surrozen presently has a consensus target price of $42.00, suggesting a potential upside of 75.18%. BioHarvest Sciences has a consensus target price of $10.00, suggesting a potential upside of 181.61%. Given BioHarvest Sciences' higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioHarvest Sciences beats Surrozen on 9 of the 17 factors compared between the two stocks.

How does BioHarvest Sciences compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 181.61%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BioHarvest Sciences had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for Neoleukin Therapeutics. BioHarvest Sciences' average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
BioHarvest Sciences	Very Positive

Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

BioHarvest Sciences has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
BioHarvest Sciences	$35.16M	1.98	-$11.14M	-$0.59	N/A

Neoleukin Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Neoleukin Therapeutics' return on equity of -37.22% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Summary

BioHarvest Sciences beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to MacroGenics?

BioHarvest Sciences (NASDAQ:BHST) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, MacroGenics had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 3 mentions for MacroGenics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat MacroGenics' score of 0.63 indicating that BioHarvest Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
BioHarvest Sciences	Very Positive
MacroGenics	Positive

96.9% of MacroGenics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioHarvest Sciences presently has a consensus target price of $10.00, suggesting a potential upside of 181.61%. MacroGenics has a consensus target price of $5.50, suggesting a potential upside of 34.61%. Given BioHarvest Sciences' higher probable upside, equities analysts plainly believe BioHarvest Sciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

BioHarvest Sciences has a net margin of -32.54% compared to MacroGenics' net margin of -44.79%. BioHarvest Sciences' return on equity of -76.03% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
MacroGenics	-44.79%	-147.80%	-28.40%

BioHarvest Sciences has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

BioHarvest Sciences has higher earnings, but lower revenue than MacroGenics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.16M	1.98	-$11.14M	-$0.59	N/A
MacroGenics	$149.50M	1.74	-$74.62M	-$1.10	N/A

Summary

BioHarvest Sciences and MacroGenics tied by winning 8 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

BioHarvest Sciences has a net margin of -32.54% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Entrada Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 164.75%. BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 181.61%. Given BioHarvest Sciences' higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioHarvest Sciences has higher revenue and earnings than Entrada Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$5.74M	44.72	-$143.75M	-$3.99	N/A
BioHarvest Sciences	$35.16M	1.98	-$11.14M	-$0.59	N/A

86.4% of Entrada Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 4 more articles in the media than BioHarvest Sciences. MarketBeat recorded 5 mentions for Entrada Therapeutics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat Entrada Therapeutics' score of 0.27 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
BioHarvest Sciences	Very Positive

Summary

Entrada Therapeutics and BioHarvest Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

BioHarvest Sciences has lower revenue, but higher earnings than Fulcrum Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.01	-$74.88M	-$1.15	N/A
BioHarvest Sciences	$35.16M	1.98	-$11.14M	-$0.59	N/A

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat Fulcrum Therapeutics' score of 0.19 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulcrum Therapeutics	Neutral
BioHarvest Sciences	Very Positive

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fulcrum Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Fulcrum Therapeutics' return on equity of -27.80% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Fulcrum Therapeutics currently has a consensus price target of $8.20, indicating a potential upside of 127.27%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 181.61%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Summary

Fulcrum Therapeutics beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks.

Get BioHarvest Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHST vs. The Competition

Export

Metric	BioHarvest Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64.05M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-5.53	20.05	24.05	24.76
Price / Sales	1.98	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.73	8.16	10.69	6.90
Net Income	-$11.14M	$23.89M	$3.57B	$337.45M
7 Day Performance	13.81%	3.66%	1.56%	2.84%
1 Month Performance	-13.39%	1.69%	2.49%	4.78%
1 Year Performance	-50.68%	46.95%	26.51%	33.08%

BioHarvest Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHST BioHarvest Sciences	3.1461 of 5 stars	$3.55 +11.0%	$10.00 +181.6%	-55.6%	$64.05M	$35.16M	N/A	N/A
SRZN Surrozen	3.7704 of 5 stars	$21.52 -11.7%	$42.00 +95.2%	+146.7%	$249.85M	$3.48M	N/A	80
NLTX Neoleukin Therapeutics	N/A	$26.49 -3.6%	N/A	+47.3%	$248.95M	N/A	N/A	90
MGNX MacroGenics	2.5097 of 5 stars	$3.91 -8.0%	$5.50 +40.7%	+160.5%	$248.53M	$149.50M	N/A	430	News Coverage
TRDA Entrada Therapeutics	3.7438 of 5 stars	$6.37 -9.0%	$18.25 +186.5%	-14.9%	$247.29M	$25.42M	N/A	110	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BHST) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioHarvest Sciences (BHST) Competitors

BHST vs. SRZN, NLTX, MGNX, TRDA, and FULC

How does BioHarvest Sciences compare to Surrozen?

Summary

How does BioHarvest Sciences compare to Neoleukin Therapeutics?

Summary

How does BioHarvest Sciences compare to MacroGenics?

Summary

How does BioHarvest Sciences compare to Entrada Therapeutics?

Summary

How does BioHarvest Sciences compare to Fulcrum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioHarvest Sciences (BHST) Competitors

BHST vs. SRZN, NLTX, MGNX, TRDA, and FULC

How does BioHarvest Sciences compare to Surrozen?

Does the media prefer SRZN or BHST?

Is SRZN or BHST more profitable?

Which has preferable valuation & earnings, SRZN or BHST?

Which has more volatility and risk, SRZN or BHST?

Do analysts prefer SRZN or BHST?

Do insiders & institutionals have more ownership in SRZN or BHST?

Summary

How does BioHarvest Sciences compare to Neoleukin Therapeutics?

Do analysts rate NLTX or BHST?

Do institutionals & insiders believe in NLTX or BHST?

Does the media refer more to NLTX or BHST?

Which has more risk & volatility, NLTX or BHST?

Which has stronger valuation and earnings, NLTX or BHST?

Is NLTX or BHST more profitable?

Summary

How does BioHarvest Sciences compare to MacroGenics?

Does the media favor BHST or MGNX?

Do insiders and institutionals hold more shares of BHST or MGNX?

Do analysts rate BHST or MGNX?

Is BHST or MGNX more profitable?

Which has more risk & volatility, BHST or MGNX?

Which has higher earnings & valuation, BHST or MGNX?

Summary

How does BioHarvest Sciences compare to Entrada Therapeutics?

Is TRDA or BHST more profitable?

Do analysts recommend TRDA or BHST?

Which has better valuation & earnings, TRDA or BHST?

Do insiders & institutionals hold more shares of TRDA or BHST?

Which has more risk & volatility, TRDA or BHST?

Does the media refer more to TRDA or BHST?

Summary

How does BioHarvest Sciences compare to Fulcrum Therapeutics?

Which has preferable valuation and earnings, FULC or BHST?

Does the media prefer FULC or BHST?

Do insiders & institutionals hold more shares of FULC or BHST?

Is FULC or BHST more profitable?

Do analysts prefer FULC or BHST?

Which has more volatility and risk, FULC or BHST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools